Researchers at Texas A&M University are working on a handheld spectrometer that could provide a cannabis crop’s THC content.
While “pot for pets” has gained popularity in recent years, the US Food and Drug Administration has yet to approve CBD-based drugs for animals.
In states with legal adult use, the age has been set at twenty-one. In Canada, it’s eighteen. New research suggests it’s “optimal” somewhere in the middle.
Canopy Growth, Curaleaf, Tilray, and Cronos—all announced research partnerships with universities across the world. And such relationships can be delicate.
A University of Miami epidemiologist shares early findings on COVID-19 and cannabis with Cannabis Wire.
The exact cause of the serious, sometimes fatal vaping-related lung injuries remains unclear.
In 2016, the US Drug Enforcement Administration said it would, for the first time, open applications for those hoping to become federally-licensed cannabis researchers. The details came four years later.
Cannabis Wire spoke with the CDC’s National Institute for Occupational Safety and Health about the emerging cannabis industry and its workers.
Research from Penn State looks at Denver, Colorado and suggests that legalization is, at worst, neutral, but likely positive for hospitality.
In a Q&A, the founder of one of the companies hoping for a federal license to supply researchers shares the frustrations of the process.
“I think the increases are mainly driven by boomers who use weed aging into the 65 and older age bracket,” the study’s senior author told Cannabis Wire.
Among the more than thirty applicants with the Drug Enforcement Administration are big names, from Canopy Growth to Battelle.
A regulatory standards expert describes a patchwork system, the need for consistent rules to protect consumers, and the need for research to properly set those rules.
The CDC on Friday confirmed a decline in reports of vaping-related lung illnesses.
A new brewing process could not only be more cost-effective than cannabis cultivation, but could allow scientists to access possibly beneficial compounds that are present at lower levels in the plant.
“This will meet the need created by the increase in the amount of approved research involving marijuana,” the DEA told Cannabis Wire.